CMS Open Payments · Program Year 2024
CeQur Corporation
CeQur Corporation reported $420,097.59 across General Payments, Research, and Ownership to 9,797 physicians and teaching hospitals across 9,797 transactions.
- $420.1K Above-median payer
- All-tracks total
- 9,797 Top quartile volume
- Transactions
- 9,797 Top quartile reach
- Recipients
- +$92.7K
- General Payments vs PY2023
CeQur Corporation reported $420,097.59 across all CMS Open Payments tracks (General + Research + Ownership) to 9,797 physicians and teaching hospitals in Program Year 2024 - ranking #807 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $420,097.59, averaging $42.88 per recipient.
How CeQur Corporation's $420.1K all-tracks total breaks down
CeQur Corporation's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
57/100
Total payments
F
14/100
Transaction volume
B
81/100
Physician reach
B
84/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer cequr-corporation CeQur Corporation
$420.1K · #807/1,925 · 0.0% industry · PY2024
- TOT $420.1K
- RANK #807
- SHARE 0.0%
- TXN 9,797
- RCP 9,797
- CAT 4
- GEN $420.1K
- ΔGEN +$92.7K
- TOP1 9.8%
- PY 2024
Volume peers
Nearest volume peer: Bio-Rad Laboratories, Inc. ($421.2K)
CeQur Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
CeQur Corporation's CMS-reported General Payments increased by $92.7K (+28.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CEQUR CORPORATIONPY2023: CEQUR CORPORATIONPY2024: CeQur Corporation. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $327,402.42
- PY2024
- $420,097.59
What the Data Shows for CeQur Corporation
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For CeQur Corporation, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Food and Beverage" leads the 4-category general-payment breakdown below at $208.3K (49.6% of General Payments, 9,607 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 4 types of general payments, CeQur Corporation's largest category was "Food and Beverage" at $208.3K - 49.6% of General Payments.
CeQur Corporation reports 4 general-payment categories - the top three are Food and Beverage (49.6%), Compensation for Services Other Than Consulting (39.7%), and Consulting Fee (9.5%). The remaining 1 category make up 1.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How CeQur Corporation divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $208.3K | 9,607 | 49.6% |
| Compensation for Services Other Than Consulting | $166.7K | 159 | 39.7% |
| Consulting Fee | $40.0K | 10 | 9.5% |
| Travel and Lodging | $5.0K | 21 | 1.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $80,602.57 (19.2%) of $420,097.59 in this company's General Payments records across 3,366 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for CeQur Corporation
The five named recipients with the highest reported General Payments from this company
- 1
Brian Levy
$41,005.30 across 13 reported transactions
- 2
Amit Bhargava
$12,092.15 across 56 reported transactions
- 3
Vinay Kapoor
$9,473.36 across 47 reported transactions
- 4
Alyssa K Greenleaf
$9,095.13 across 19 reported transactions
- 5
Kalpana Reddy
$8,936.63 across 53 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
CeQur Corporation ranks #807 of 1,925 by total payments (top 42% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,614 of 1,838 by HHI (bottom 12% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Fortis Surgical, LLC : $45.6K total payments, HHI 163
- Deciphera Pharmaceuticals Inc. : $602.7K total payments, HHI 162
- Radius Health, Inc. : $792.8K total payments, HHI 162
- Kuros Biosciences USA, Inc : $711.3K total payments, HHI 162
- Merz Pharmaceuticals, LLC : $919.5K total payments, HHI 162
- Vanda Pharmaceuticals Inc. : $4.6M total payments, HHI 160
- CeQur Corporation (this company) : $420.1K total payments, HHI 160
- Kiniksa Pharmaceuticals International, plc : $1.7M total payments, HHI 159
- Lundbeck LLC : $4.1M total payments, HHI 159
- Foundation Fusion Solutions, LLC : $106.1K total payments, HHI 157
- Heartflow, Inc. : $1.7M total payments, HHI 157
- Globus Medical, Inc. : $27.0M total payments, HHI 156
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as CeQur Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about CeQur Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with CeQur Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
WyCo Surgical Distribution LLC
Rayner Intraocular Lenses Limited
Almatica Pharma LLC
Incline Medical
Visioneering Technologies, Inc.
Put this to use
CeQur Corporation ranks #807 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just CeQur Corporation. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.